CellAegis Devices Inc. - Media Coverage
The science behind the CellAegis autoRIC™ Device System has been selected as one of Canada’s top 10 game-changing health technologies by The Canadian Network for Environmental Scanning in Health at the 2014 Canadian Agency for Drugs and Technologies in Health Symposium in April. CellAegis has exclusive rights to the technology developed at Sick Kids.
CellAegis Devices: 2012 Mind to Market Award Finalist
CellAegis autoRIC™ Device
European Hospital Early Adopter Program
Safe for your patient, Simple for you!
Preferred Consumables Pricing
Capital Costs Eliminated
Three-year warranty on Device(s)
Better Cath Lab Outcomes, Improved Clinical Benefit
pPCI: Infarct size reduction, MACE & mortality reduced
ePCI: Troponin and MACCE reductions
Coronary Angiogram/TAVR: Significant reduction in CI-AKI
For more information about the autoRIC™ Device or to inquire about our European Hospital Early Adopter Program:
Call us: 1-647-722-9601 Email us: email@example.com